Classifying patients as GOLD A–D using the 2017 strategy criteria: impact on efficacy by GOLD stage in the OTEMTO tiotropium+olodaterol clinical trials Source: International Congress 2017 – What is new in COPD diagnosis and classification? Year: 2017
CIPHER: a prospective, multicentre study for the identification of biomarker signatures for early detection of pulmonary hypertension Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension Year: 2020
Towards the next stage of novel biomarker discussion in COPD: Tekizai-Tekisho Source: Eur Respir J 2014; 43: 322-324 Year: 2013
Development of a new prognosis index (BODS) in patients with COPD:a prospective cohort study Source: International Congress 2018 – What’s hot in rehabilitation in COPD and interstitial lung disease (ILD)? Year: 2018
GOLD classification of COPD and subsequent mortality: findings from a cohort study Source: Annual Congress 2004 - Burden of obstructive lung diseases: costs, mortality and life impairment Year: 2004
Prediction of the clinical course of COPD using the old and the new GOLD classification Source: Annual Congress 2012 - GOLD guidelines 2011: new assessment of COPD Year: 2012
An international prospective cohort study to develop a practical COPD disease risk index that predicts the clinical course of COPD Source: Annual Congress 2009 - Comorbidities and case management in primary respiratory care Year: 2009
GOLD classification of COPD and incident lung cancer: findings from a cohort study Source: Eur Respir J 2004; 24: Suppl. 48, 269s Year: 2004
Validation of non-spirometric predictors of COPD to the GOLD stage classification Source: Eur Respir J 2002; 20: Suppl. 38, 123s Year: 2002
Stage 0 in GOLD does not predict future clinical COPD Source: Eur Respir J 2002; 20: Suppl. 38, 401s Year: 2002
COPD specific comorbidities: A prospective, objective and controlled evaluation Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases Year: 2016
Pneumonia risk with budesonide-containing therapies in COPD: pooled analysis of three Phase III studies Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019
FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts Source: Eur Respir J 2013; 42: 1391-1401 Year: 2013
Implementation of the GOLD 2017 disease classification in a real-life COPD cohort Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018
An Italian, observational, multicenter trial to describe the therapeutic approach according to COPD GOLD guidelines during three years of observation: The MISTRAL study Source: International Congress 2014 – Clinical assessment of airway diseases Year: 2014
Novel patterns of serum biomarkers profiling using minimal important clinical outcomes (MICO) in the longidutinal study BODE cohort of COPD patients Source: Annual Congress 2010 - COPD: symptoms and staging Year: 2010
Identification and analysis of clinical phenotypes in COPD patients: PALOMB Cohort Source: Virtual Congress 2021 – COPD burden, epidemiology and management Year: 2021
Is GOLD stage 0 a good predictor of the development of COPD? Preliminary results from the ECRHS II Source: Eur Respir J 2005; 26: Suppl. 49, 434s Year: 2005
COPD and Seretide: a multi-centre intervention and characterisation (COSMIC) study: rationale and baseline characteristics Source: Eur Respir J 2002; 20: Suppl. 38, 241s Year: 2002
LATE-BREAKING ABSTRACT: Biomarkers of ECM turnover and clinical relevant outcomes in COPD: Results of the multicenter PROMISE study Source: International Congress 2015 – Notable abstracts in COPD: variety Year: 2015